




**SOA IN HEALTHCARE CONFERENCE**  
*Improving Health Through Technology:  
The Role of SOA on the Path to Meaningful Use*  
July 12-14, 2010, The Westin Arlington Gateway, Arlington, VA USA

## Enabling Technologies for Healthcare Transformation & SOA

**Chalapathy Neti, Shahram Ebadollahi, Sridhar Iyengar, Henry Chang\***  
**IBM TJ Watson Research Centre**



## A new Healthcare Ecosystem needs to ...

- Integrated
- Enabled by data-driven evidence
- Be measured and driven to deliver patient outcomes
- Be more efficient and economical
- Present growth opportunities for ecosystem participants
- Deliver better quality healthcare for all



## IBM Point of View

### Thesis

The industry is moving towards an **Evidence-centric healthcare ecosystem** to drive healthcare transformation and yield lower costs and improved outcomes

### Change Implications

Proper alignment of payment and incentives to evidence-centric healthcare delivery, along with large-scale comparative effectiveness evidence generation and delivery platforms is critical to drive this transformation

### IBM Response

- ◆ **Participate and lead transformation of Healthcare delivery models** like Patient Centered Medical Home
- ◆ **Deliver business analytics solutions that facilitate the implementation of evidence-centric models** through service, software and cloud computing capabilities

The healthcare transformation at Geisinger is an example of how an evidence-centric ecosystem with novel incentives, comprehensive digitization of EHR, and analytics for identifying best practices can enable improved outcomes and operational efficiency


### ***Geisinger ProvenCare (CABG)***

- ***Implemented EHR in 1995, CDIS in 2009***
- ***Developed best practice guidelines in 2008***
- ***ProvenCare/Acute episodic care program provides warranty on outcomes***


Benefits

- *Readmission within 30 days (6.9% → 3.8%) ; average total Length of Stay (LOS): (6.2d → 5.7d)*
- *Reduced hospital mortality (1.5% → 0%); number of Neurological complications (1.5% → 0.6%) ;*


## IBM is focused on four enabling capabilities for healthcare transformation




## IBM is focused on four enabling capabilities for healthcare transformation



Emerging early diagnosis allows improved observation of the body's internal state before clinical symptoms appear. **Earlier intervention results in improved outcomes and lower costs.**



Evidence delivery at the point-of-care is enhanced by providing clinical decision intelligence via consumable delivery of evidence from up to date evidence sources and aggregators







# Example: Cardiac Clinical Decision Support System (contact: Dr. Tanveer Syeda-Mahmoud)



## Current diagnosis practice:


1. Physician makes a diagnosis based on a single patient's data and her prior experience.
2. No validation of diagnosis other than through second opinions.

## With a Clinical Decision Support System:

1. Physician makes a diagnosis as before.
2. A holistic model of the patient and his data – EKG, echo video, heart sounds, demographics,... is submitted to the CDI for feature extraction.
3. The patient's feature model is used to find pre-diagnosed (confirmed) patients with 'similar' feature models.
4. System supplies statistics relating to diagnoses for these similar patients.
5. Physician validates/re-considers her diagnosis using the patient data, supplied statistics and 'similar' patient data.



## AALIM: A System for Diagnostic Decision Support for Cardiac Patients




Login	Select Patients	Overview	Longitudinal	Contextual	Logout
-------	-----------------	----------	--------------	------------	--------


ARN:	03940-000-07-00001	A fictitious patient
Name:	KEITH CHAN	
Gender:	M	
Age:	89	
Conditions based on:	<input checked="" type="checkbox"/> OSCR <input type="checkbox"/> EKG <input type="checkbox"/> TEXT <input type="checkbox"/> ECHO	
Key:	<div>applies to patient</div> <div>does not apply to patient</div>	

Common Conditions			Common Drugs		
<div></div>	[90%]	401.9	Unspecified (Essential hypertension)	<div></div>	angiotensin converting en: inhibitors
<div></div>	[90%]	427.31	Atrial fibrillation (Cardiac dysrhythmias: Atrial fibrillation and flutter)	<div></div>	cardioselectiv blockers
<div></div>	[80%]	424.0	Mitral valve disorders (Other diseases of endocardium)	<div></div>	first generatio cephalosporin
<div></div>	[80%]	424.1	Aortic valve disorders (Other diseases of endocardium)	<div></div>	loop diuretics
<div></div>	[70%]	394.0	Mitral stenosis (Diseases of mitral valve)	<div></div>	coumarins an indandiones
<div></div>	[65%]	428.0	Congestive heart failure, unspecified (Heart failure)	<div></div>	adrenergic bronchodilato
<div></div>	[45%]	443.9	Peripheral vascular disease, unspecified (Other peripheral vascular disease)	<div></div>	glucocorticoid
<div></div>	[40%]	459.81	Venous (peripheral) insufficiency, unspecified (Other disorders of circulatory system: Other specified disorders of circulatory system)	<div></div>	H2 antagonist
<div></div>	[40%]	429.9	Heart disease, unspecified (Ill-defined descriptions and complications of heart disease)	<div></div>	macrolides
<div></div>	[35%]	424.2	Tricuspid valve disorders, specified as nonrheumatic (Other diseases of endocardium)	<div></div>	aminopenicilli
<div></div>	[35%]	427.9	Cardiac dysrhythmia, unspecified (Cardiac dysrhythmias)	<div></div>	nasal steroids
<div></div>	[35%]	424.9	Endocarditis, valve unspecified, unspecified cause (Other diseases of endocardium: Endocarditis, valve unspecified)	<div></div>	nonsteroidal anti-inflamma agents
<div></div>	[35%]	428.1	Left heart failure (Heart failure)	<div></div>	quinolones
<div></div>	[35%]	428.0	Unspecified transient cerebral ischemia	<div></div>	narcotic analg
				<div></div>	inotropic ager
				<div></div>	phenothiazine antiemetics
				<div></div>	Statins
				<div></div>	topical steroid
				<div></div>	miscellaneous


## IBM is focused on four enabling capabilities for healthcare transformation




Evidence services platforms (e.g., Cloud) enable data aggregation, evidence extraction, synthesis and dissemination to consumers, providers, payers, pharma, individuals, regulators...



### Trends



Emergence of large scale consortia for data and evidence sharing



Emergence of innovative companies for evidence generation & delivery

Not for publication on OMG Web Site

# Example - EUResist: HAART Therapy Prediction

(Dr. Michal Rosen-Zvi, IBM Research, Haifa)

Predicts in-vivo efficacy of anti-retroviral drug regimens, i.e., reduction in viral load.

Combines 3 Machine Learning Predictive Technologies

Uses Viral Genome and Patient demographic and clinical data

Outperforms leading available resistance interpretation system

Available on-line at:


<http://engine.euresist.org>

2009 Computerworld Honors Program Finalist


## Prediction System



IBM's HRL with EU researchers from Germany, Italy, Hungary, and England.




## IBM is focused on four enabling capabilities for healthcare transformation






Outcome based payment incentives lead to improved outcomes and demand for evidence at point of care. This requires large scale evidence generation and comparative effectiveness clouds.






Availability of up-to-date evidence from evidence-aggregators enables the development of evidence-informed, outcome-based payment modeling and contract optimization services




# 'What-if' analytics for chronic disease care optimization


*Selection of process and outcome targets and corresponding payments can be optimized to yield cost savings and better quality of care*



## IBM is focused on four enabling capabilities for healthcare transformation




We envision the **emergence of brokerage businesses that aggregate evidence** and provide customized delivery to various constituents (e.g. disease-specific evidence)






# Healthcare Transformation and SOA

# SOA Reference Architecture



# Health Integration Framework – Model


- The Health Integration Framework (HIF) provides a unifying structure (architecture and mindset) for our solution offerings, go-to-market, partner enablement and asset development strategies.
- This SOA-based approach enables our customers greater flexibility and enhances the effective use of their previously siloed departmental islands of data.




## Key SOA Standards from OMG and OASIS Relevant to Healthcare

- Business Modeling : Business Process Model & Notation (OMG BPMN)
  - Design and simulate Healthcare Business Processes is becoming more common
- Application & Service Design : Unified Modeling Language (OMG UML), Service Oriented Architecture Modeling Language (OMG SoaML)
  - Design of Application Architecture using UML is also becoming more common
  - Design of Services using OMG SoaML is emergent
- SOA Infrastructure standards
  - Service Component Architecture (Oasis SCA)
  - Business Process Execution Language (Oasis BPEL)







## Rapid Deployment – Initiate Exchange – SAAS + Appliance



# IBM's Collaborative Care Cloud Solution



# IBM Information Agenda



## The transformed Healthcare Ecosystem...

- Is integrated
- Is enabled by data-driven evidence
- Is measured and driven to deliver patient outcomes
- Is more efficient and economical
- Presents growth opportunities for ecosystem participants
- Should deliver better quality healthcare for all